SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following the announcement of a private exchange of $1.4 billion in convertible notes for equity, a move that the community is actively debating as either a strategic debt reduction or a potential dilution event. While some investors remain cautious about the near-term price impact, others interpret the debt-for-equity swap as a bullish signal that could precede future corporate acquisitions or strategic business moves.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing significant downward pressure as investors brace for a massive insider share unlock that begins shortly after the company's first public earnings report. While bearish sentiment is high due to fears of dilution and valuation concerns, many community members are debating whether this volatility represents a generational buying opportunity or a deeper correction toward double-digit price levels.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining momentum as investors weigh a strong commercial performance for Briumvi against ongoing short seller activity and analyst price target adjustments. The community remains focused on potential pipeline expansion into indications like schizophrenia and myasthenia gravis, while speculative discussions regarding a possible buyout continue to drive engagement.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending following a strong quarterly earnings report that highlighted robust store expansion and solid revenue growth, fueling community speculation about a potential future relisting. Investors are actively discussing the company's margin trajectory and the ongoing share repurchase program, balancing optimism over market dominance against concerns regarding same-store sales and the OTC trading environment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors weigh strong AI-driven memory demand against concerns over potential Chinese fabrication competition and broader sector volatility. While the community is actively debating the sustainability of the memory supercycle, bullish sentiment remains focused on long-term hyperscaler capital expenditure and robust earnings potential through 2030.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is seeing renewed market attention driven by its strategic expansion into oncology through high-profile licensing deals and collaborative AI-driven research. Investors are closely monitoring the company's ability to balance its robust growth portfolio against significant upcoming patent expirations for key legacy blockbusters.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant investor focus following reports of preliminary, high-value merger discussions with Bristol Myers Squibb that would create a major pharmaceutical giant. The community is actively debating the potential for massive operational synergies through cost-cutting and headcount reductions, while also weighing the complex antitrust risks that such a significant oncology-focused consolidation would face from regulators.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The DJIA is currently experiencing significant volatility fueled by intense geopolitical uncertainty in the Middle East and ongoing skepticism toward Trump's proposed diplomatic deals. Community discourse is heavily fragmented, with market participants debating whether the current market environment represents a genuine rally or a precarious bubble susceptible to a major correction.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing significant volatility following a mixed earnings report that missed analyst expectations, leading to several downgrades and increased caution among investors. The community is actively debating the company's valuation versus its long-term potential as a U.S.-based solar manufacturing leader in the face of shifting trade policies and competitive pressures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors eagerly anticipate topline results from the Phase 3 IZAR-1 trial for sonelokimab, a key catalyst expected to demonstrate best-in-class efficacy in psoriatic arthritis. The community is actively debating the precise timing of this data release following management's recent guidance, while simultaneously weighing the potential for a significant M&A event given the stock's strong institutional backing and multi-indication pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kensington Capital Acquisition Corp. V operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on March 19, 2021 and is headquartered in Westbury, NY.

Kensington Capital Acquisition Corp V - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.18
Prev Close	$11.17
Open	$11.18
Dividend Yield	N/A
50-Day Moving Average	$11.11
Beta	-0.14
Avg. Volume	12,145.77
PE Ratio	22.40

52-Week High	$11.19
52-Week Low	$10.49
Market Capitalization	$0.00
EPS (Annual)	N/A
Price to Book	3.42
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info